Latest Conference Articles

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Results of the CARAVAGGIO trial found oral apixaban was noninferior to subcutaneous dalteparin for preventing cancer-associated VTE without increasing a patient’s risk for major bleeding.

Results of the SPYRAL-HTN OFF MED indicate renal denervation could prove useful for lowering SBP in patients with untreated hypertension.

Marc Bonaca, MD, discusses the results of a subgroup analysis examining the impact of concomitant clopidogrel use in VOYAGER-PAD study.

New PRONOMOS data shows patients receiving lower limb surgery benefit significant from the oral anticoagulant—without increased risk of bleeding.

Results of POPular TAVI indicate concomitant clopidogrel with oral anticoagulants increases risk of bleeding in patients requiring long-term anticoagulation after TAVI.

New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.

A new ACC 2020 study shows the modifiable levels of CVD risk are distinguishable to long-term event possibility.

A heart failure and transplant cardiologist assesses the new study findings.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.

Data presented at ACC.20/WCC is shedding light on the impact of genotype-guided antiplatelet therapy in patients undergoing PCI for ACS or CAD.

New VICTORIA findings show the novel therapy may reduce risk of severe outcomes among high-risk patients with HFrEF.

Discussing the impact of COVID-19 on ACC.20/WCCardio and the cardiology community throughout the country.

Allergic rhinitis is the most frequent atopic coexisting disease in the LIBERTY ASTHMA VENTURE study.

Discussing how approval of bempedoic acid impacts the role of PCSK9 inhibitors for lowering LDL-C.

New findings show eligible men and minority group patients are less likely to receive a fill for the novel drug class.